Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Heidi Pence

Registered Nurse Phoenix, AZ Nurse Practitioner

NPI 1245330224 CMS profile 11046750

1037 E Missouri Ave, Phoenix, AZ 85014

Open in the dashboard

General payments

$1,065

78 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heidi Pence of Phoenix, AZ is reported in the CMS Open Payments database as having received $1,065 across 78 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Registered Nurse profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15 1
2024 General $170 29
2023 General $19 2
2022 General $507 25
2021 General $354 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heidi Pence
  • Registered Nurse median
  • Middle half of Registered Nurse
  • National median

In program year 2025, general payments to Heidi Pence were reported at $15. Among 1,661 Registered Nurse profiles paid that year, the median was $74 and the middle half received between $27 and $193.

Show as a table
Year Heidi Pence Registered Nurse median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $354 $53 $20–$148 $132
2022 $507 $53 $21–$146 $149
2023 $19 $84 $26–$196 $160
2024 $170 $80 $26–$187 $164
2025 $15 $74 $27–$193 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $711 58 payments
  2. ITI, Inc. $261 13 payments
  3. Sunovion Pharmaceuticals Inc. $75 6 payments
  4. Alkermes, Inc. $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,065 78 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $711 58 payments
  2. CAPLYTA Psychiatry $246 12 payments
  3. LATUDA $75 6 payments
  4. LYBALVI $18 1 payment
  5. ARISTADA Cns $18 1 payment
  6. ARISTADA Cns $18 1 payment
  7. ARISTADA Cns $18 1 payment
  8. ARISTADA Cns $18 1 payment
  9. CAPLYTA Psychiatry $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,702

Median for Registered Nurse: 109

Drug cost

$60,583

Median for Registered Nurse: $4,454

Branded share of claims

18.4%

Median for Registered Nurse: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nuedexta Dextromethorphan Hbr/Quinidine Brand 13 $23,745
Belsomra Suvorexant Brand 13 $5,368
Lisdexamfetamine Dimesylate Generic 19 $3,439
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 60 $2,682
Quetiapine Fumarate Generic 118 $2,645
Oxcarbazepine Generic 20 $2,439
Venlafaxine Hcl Er Venlafaxine Hcl Brand 59 $2,203
Aripiprazole Generic 78 $2,133
Duloxetine Hcl Generic 127 $1,879
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 34 $1,832

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 476 Part D prescribers listed as Registered Nurse; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $152
$152 — —
ARISTADA
  • Alkermes, Inc. $14
$14 — —
LYBALVI
  • Alkermes, Inc. $4
$4 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record